Search research articles
Contact Us
Filters
Showing results (221-230 of 229) with videos related to
Page
of 23
Sort By:
You have reached the last page of results.
This site can display upto 229 results.
British Journal of Cancer
|
June 19, 2015
Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma
M E Gore, C Szczylik, C Porta, et al.
ESMO Open
|
December 5, 2021
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with renal cell carcinoma
R Kanesvaran, C Porta, A Wong, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 5, 2026
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial
T K Choueiri, L Albigès, D F McDermott, et al.
ESMO Open
|
December 9, 2022
Validation of the Meet-URO score in patients with metastatic renal cell carcinoma receiving first-line nivolumab and ipilimumab in the Italian Expanded Access Program
S E Rebuzzi, A Signori, S Buti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 4, 2024
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial
N M Tannir, L Albigès, D F McDermott, et al.
ESMO Open
|
December 5, 2023
Confirmatory validation analysis of the PROFFIT questionnaire to assess financial toxicity in cancer patients
L Arenare, C Porta, D Barberio, et al.
Journal of Cancer Policy
|
October 6, 2025
Longitudinal validation of the PROFFIT questionnaire to assess financial toxicity in cancer patients
L Arenare, C Porta, D Barberio, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 16, 2015
Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project†
A Kramar, S Negrier, R Sylvester, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 19, 2026
ESMO Adaptation of Lines of Systemic Therapy (EnLiST): a consensus framework for standardising the designation of lines of therapy in solid tumours
K S Saini, M Koopman, D Martins-Branco, et al.
Page
of 23
Search research articles
Search
Showing results (221-230 of 229) with videos related to
Sort By:
Page
of 23
You have reached the last page of results.
This site can display upto 229 results.
British Journal of Cancer
|
June 19, 2015
Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma
M E Gore, C Szczylik, C Porta, et al.
ESMO Open
|
December 5, 2021
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with renal cell carcinoma
R Kanesvaran, C Porta, A Wong, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 5, 2026
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial
T K Choueiri, L Albigès, D F McDermott, et al.
ESMO Open
|
December 9, 2022
Validation of the Meet-URO score in patients with metastatic renal cell carcinoma receiving first-line nivolumab and ipilimumab in the Italian Expanded Access Program
S E Rebuzzi, A Signori, S Buti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 4, 2024
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial
N M Tannir, L Albigès, D F McDermott, et al.
ESMO Open
|
December 5, 2023
Confirmatory validation analysis of the PROFFIT questionnaire to assess financial toxicity in cancer patients
L Arenare, C Porta, D Barberio, et al.
Journal of Cancer Policy
|
October 6, 2025
Longitudinal validation of the PROFFIT questionnaire to assess financial toxicity in cancer patients
L Arenare, C Porta, D Barberio, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 16, 2015
Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project†
A Kramar, S Negrier, R Sylvester, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 19, 2026
ESMO Adaptation of Lines of Systemic Therapy (EnLiST): a consensus framework for standardising the designation of lines of therapy in solid tumours
K S Saini, M Koopman, D Martins-Branco, et al.
Page
of 23